Small molecule · Inhibitor of cyclin-dependent kinase 2 (CDK2) · developed by ASTRAZENECA
Gatsuciclib is an orally bioavailable small molecule that selectively binds and inhibits cyclin-dependent kinase 2 (CDK2), a serine/threonine kinase that regulates cell cycle progression. Inhibition of CDK2 is intended to cause cell cycle arrest and apoptosis in tumor cells. It is being studied in ER+ HER2- advanced breast cancer and high-grade serous ovarian cancer.
Summary written with AI from the sources listed at the end of this page.
ER+ HER2- Advanced Breast CancerHigh-grade Serous Ovarian Cancer (HGSOC)
See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
AZN catalysts and pipeline →